Home
Coverage
Anixa Biosciences
Atomera
INmune Bio
Lantern Pharma
ParkerVision
Quest Resource Holding
Spectra7
TFF Pharmaceuticals
Members
Current Holdings & Performance
Trading Blog
Zoom Calls…
Newsletter
Monthly Performance Reviews
Weekly Newsletters
About
About
Contact Us
Privacy Policy
Disclaimer
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Password recovery
Recover your password
your email
Search
Member Login
Login
Reset Password
Become a Member
Contact Us
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
TW Research Group
Home
Coverage
Anixa Biosciences
Atomera
INmune Bio
Lantern Pharma
ParkerVision
Quest Resource Holding
Spectra7
TFF Pharmaceuticals
Members
Current Holdings & Performance
Trading Blog
Zoom Calls…
Newsletter
Monthly Performance Reviews
Weekly Newsletters
About
About
Contact Us
Privacy Policy
Disclaimer
Daniel Carlson
2224 POSTS
765 COMMENTS
Front Page
My Rally Cap is On!
Daniel Carlson
-
December 2, 2023
11
Front Page
Trading Thoughts…Premium Subscriber Update
Daniel Carlson
-
November 30, 2023
3
Front Page
Movano Health Announces Over $1M Black Friday Holiday Launch Results for...
Daniel Carlson
-
November 29, 2023
0
Front Page
INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab...
Daniel Carlson
-
November 29, 2023
0
Front Page
INmune Bio Receives EMA’s Authorization in France and Spain for Phase...
Daniel Carlson
-
November 27, 2023
0
Anixa
Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology
Daniel Carlson
-
November 27, 2023
0
Front Page
The Outlook For December
Daniel Carlson
-
November 25, 2023
9
Front Page
IN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed...
Daniel Carlson
-
November 20, 2023
6
Front Page
Turkey Day is Coming…Micro-Caps Have Been Turkeys For A While
Daniel Carlson
-
November 18, 2023
4
Front Page
Movano Health Announces Closing of $4.1 Million Public Offering Including Full...
Daniel Carlson
-
November 17, 2023
0
enVVeno
enVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE)...
Daniel Carlson
-
November 16, 2023
0
Front Page
The Year End Game Plan (part 2)…Premium Subscriber Update
Daniel Carlson
-
November 15, 2023
3
Front Page
INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for...
Daniel Carlson
-
November 15, 2023
2
Atomera
Atomera Achieves Revenue Milestone Under First Commercial License Agreement
Daniel Carlson
-
November 14, 2023
0
Front Page
It’s Not A Sprint (It’s a Marathon)
Daniel Carlson
-
November 10, 2023
7
Front Page
TFF Pharmaceuticals Announces Publication of Data Demonstrating Feasibility of Intranasal Delivery...
Daniel Carlson
-
November 10, 2023
0
Front Page
IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to...
Daniel Carlson
-
November 10, 2023
0
Front Page
IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial...
Daniel Carlson
-
November 6, 2023
0
Front Page
Rates Cease Their Upward March (for now…)
Daniel Carlson
-
November 4, 2023
2
Front Page
IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC)...
Daniel Carlson
-
November 3, 2023
0
Front Page
IN8bio to Present New Positive Data from Phase 1 Trial of...
Daniel Carlson
-
November 2, 2023
0
Anixa
Anixa Biosciences to Present at the Ovarian Cancer Research Alliance (OCRA)...
Daniel Carlson
-
October 31, 2023
0
Front Page
Movano Health’s Proprietary Chip and Prototype Achieves Accuracy Commensurate with the...
Daniel Carlson
-
October 31, 2023
0
Front Page
INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™...
Daniel Carlson
-
October 31, 2023
0
Front Page
INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03...
Daniel Carlson
-
October 30, 2023
0
Front Page
In Support of the XBI
Daniel Carlson
-
October 28, 2023
3
Front Page
Spectra7 Announces Preliminary Third Quarter 2023 Revenue and Updates Second Half...
Daniel Carlson
-
October 26, 2023
3
Front Page
The Year End Game Plan…Premium Subscriber Update
Daniel Carlson
-
October 24, 2023
4
Anixa
Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark...
Daniel Carlson
-
October 23, 2023
0
Front Page
Testing Support…(Not Likely to Hold in TW’s Opinion)
Daniel Carlson
-
October 21, 2023
0
Front Page
INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase...
Daniel Carlson
-
October 17, 2023
0
Front Page
Supply and Demand
Daniel Carlson
-
October 14, 2023
6
Anixa
Anixa Biosciences Completes Treatment of First Patient Cohort in Ovarian Cancer...
Daniel Carlson
-
October 13, 2023
2
Front Page
IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a...
Daniel Carlson
-
October 12, 2023
0
Front Page
Choose Wisely
Daniel Carlson
-
October 7, 2023
4
enVVeno
NVNO in the News Today…Premium Subscriber Update
Daniel Carlson
-
October 6, 2023
0
enVVeno
enVVeno Medical Announces New Expedited Development Plan for the enVVe® Transcatheter...
Daniel Carlson
-
October 6, 2023
0
enVVeno
enVVeno Medical Achieves Full Enrollment for VenoValve U.S. Pivotal Trial
Daniel Carlson
-
October 6, 2023
0
enVVeno
enVVeno Medical Announces Private Placement of $28 Million
Daniel Carlson
-
October 6, 2023
4
Anixa
Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer...
Daniel Carlson
-
October 3, 2023
0
Front Page
Time for the Little Guys to Shine…4th Quarter Preview
Daniel Carlson
-
September 29, 2023
1
Front Page
IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC)...
Daniel Carlson
-
September 29, 2023
0
Front Page
IN8bio to Host Research & Development Day on its Gamma-Delta T...
Daniel Carlson
-
September 27, 2023
0
Front Page
TW Trade Alert, Sept. 27, 2023
Daniel Carlson
-
September 27, 2023
0
Front Page
Lantern Pharma Announces First Patient Dosed in the Phase 1 Study...
Daniel Carlson
-
September 25, 2023
0
Front Page
Jumping Beans
Daniel Carlson
-
September 23, 2023
5
Front Page
IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents
Daniel Carlson
-
September 19, 2023
0
Anixa
Anixa Biosciences Establishes Cancer Business Advisory Board
Daniel Carlson
-
September 19, 2023
0
Front Page
Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation...
Daniel Carlson
-
September 18, 2023
0
Front Page
Meaningful Catalysts
Daniel Carlson
-
September 16, 2023
8
Front Page
Spectra7 Announces Convertible Debenture Unit Financing
Daniel Carlson
-
September 14, 2023
0
Front Page
Is the Ice Thawing? XBI Acting Slightly Better…
Daniel Carlson
-
September 9, 2023
0
Front Page
INmune Bio Inc. Announces Approval of Clinical Trial Application by the...
Daniel Carlson
-
September 5, 2023
0
Front Page
Wrapping up Summer
Daniel Carlson
-
September 1, 2023
1
Anixa
Anixa Biosciences Announces Treatment of Third Patient in Ovarian Cancer CAR-T...
Daniel Carlson
-
August 28, 2023
0
Front Page
Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the...
Daniel Carlson
-
August 28, 2023
0
Front Page
Know What You Own…
Daniel Carlson
-
August 25, 2023
2
Front Page
Spectra7 Announces Second Quarter 2023 Financial Results
Daniel Carlson
-
August 23, 2023
0
Front Page
Fitch Kills The Rally
Daniel Carlson
-
August 18, 2023
1
Front Page
TFF Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate...
Daniel Carlson
-
August 15, 2023
2
Front Page
Premium Subscriber Update: TFF Raises Money at $0.25…What Does It Mean?
Daniel Carlson
-
August 15, 2023
6
Anixa
Anixa Biosciences Announces Invited Presentation on Ovarian Cancer CAR-T Therapy at...
Daniel Carlson
-
August 14, 2023
0
Front Page
INmune Updates Shareholders and Other Thoughts
Daniel Carlson
-
August 12, 2023
6
Front Page
IN8bio Expands Capabilities with the Grand Opening of its Advanced Research...
Daniel Carlson
-
August 10, 2023
0
Front Page
Evie Ring Establishes Medical Advisory Board Furthering its Commitment to Bringing...
Daniel Carlson
-
August 10, 2023
0
Anixa
Could Anixa Biosciences (NASDAQ:ANIX) Be Developing The Vaccine To End One...
Daniel Carlson
-
August 10, 2023
0
Front Page
August 7, 2023…Premium Subscriber Update
Daniel Carlson
-
August 7, 2023
0
Anixa
Anixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing...
Daniel Carlson
-
August 7, 2023
0
Front Page
Asking For Compassion From TFF
Daniel Carlson
-
August 4, 2023
9
Front Page
TFF Pharmaceuticals Inc. and Uniphar Durbin Ireland Ltd. Announce the Opening...
Daniel Carlson
-
July 31, 2023
0
Front Page
XBI…Waiting For The Breakout
Daniel Carlson
-
July 29, 2023
5
Anixa
Anixa Biosciences Announces Notice of Allowance of Additional Patent on Ovarian...
Daniel Carlson
-
July 27, 2023
3
Front Page
In Search of the Holy Grail
Daniel Carlson
-
July 22, 2023
4
Front Page
July 19, 2023…Premium Subscriber Update
Daniel Carlson
-
July 19, 2023
0
Front Page
Spectra7 Announces Preliminary Second Quarter 2023 Revenue and Second Half of...
Daniel Carlson
-
July 18, 2023
0
Front Page
Things are Heating Up
Daniel Carlson
-
July 15, 2023
6
enVVeno
enVVeno Medical to Host Virtual KOL Event on July 18, 2023
Daniel Carlson
-
July 14, 2023
0
Front Page
July 14, 2023…Premium Subscriber Update
Daniel Carlson
-
July 14, 2023
0
Front Page
July 12, 2023…Premium Subscriber Update
Daniel Carlson
-
July 12, 2023
3
Front Page
INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging...
Daniel Carlson
-
July 12, 2023
0
Anixa
Anixa Biosciences Announces Issuance of Canadian Patent for its CAR-T Cancer...
Daniel Carlson
-
July 11, 2023
0
Front Page
INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in...
Daniel Carlson
-
July 11, 2023
0
Front Page
INmune Bio Inc. Announces Data Presented at the 16th European Meeting...
Daniel Carlson
-
July 10, 2023
0
Front Page
QUEST RESOURCE HOLDING CORPORATION APPOINTS INDUSTRY VETERAN, PERRY W. MOSS, AS...
Daniel Carlson
-
July 10, 2023
0
Front Page
It’s Beach Week And The Sun Was Shining On TW’s Names
Daniel Carlson
-
July 7, 2023
5
enVVeno
enVVeno Medical Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study...
Daniel Carlson
-
July 5, 2023
0
Front Page
Where to Find Fireworks? We Go Looking.
Daniel Carlson
-
July 1, 2023
5
Front Page
TFF Pharmaceuticals Awarded $2.97 Million to Develop Universal Influenza Vaccine
Daniel Carlson
-
June 28, 2023
2
Front Page
Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing...
Daniel Carlson
-
June 26, 2023
0
Front Page
Free Call Options
Daniel Carlson
-
June 23, 2023
6
Front Page
June 20, 2023…Premium Subscriber Update
Daniel Carlson
-
June 21, 2023
13
Front Page
Several Updates
Daniel Carlson
-
June 17, 2023
8
Front Page
Movano Health Prices $8.0 Million Public Offering
Daniel Carlson
-
June 13, 2023
0
Front Page
June 13, 2023…Premium Subscriber Update
Daniel Carlson
-
June 13, 2023
0
Front Page
Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate...
Daniel Carlson
-
June 12, 2023
0
Front Page
The Spotlight Turns to INmune Bio…
Daniel Carlson
-
June 10, 2023
10
Front Page
Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug...
Daniel Carlson
-
June 9, 2023
0
Front Page
June 8, 2023…Premium Subscriber Update
Daniel Carlson
-
June 8, 2023
0
Front Page
IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at...
Daniel Carlson
-
June 5, 2023
0
Front Page
Wrapping Up May
Daniel Carlson
-
June 3, 2023
8
Front Page
Keep The Faith…Rubber Eventually Meets Road
Daniel Carlson
-
May 27, 2023
9
Front Page
INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present...
Daniel Carlson
-
May 24, 2023
0
Front Page
May 22, 2023…Premium Subscriber Update
Daniel Carlson
-
May 22, 2023
3
Anixa
Anixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer...
Daniel Carlson
-
May 22, 2023
3
Front Page
Back in the Saddle
Daniel Carlson
-
May 20, 2023
3
Front Page
IN8bio’s DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer
Daniel Carlson
-
May 17, 2023
0
Front Page
Spectra7 Announces 50% Y-o-Y Revenue Growth in First Quarter 2023, Affirms...
Daniel Carlson
-
May 9, 2023
0
Newsletters
Upcoming Catalysts For A Catalyst Driven Market
Daniel Carlson
-
May 5, 2023
0
Front Page
TFF Pharmaceuticals Enters into CRADA with the National Institute of Environmental...
Daniel Carlson
-
May 4, 2023
5
Front Page
IN8bio Announces New Preclinical Data in Ovarian Cancer to be Presented...
Daniel Carlson
-
May 3, 2023
0
Front Page
May 2, 2023…Trading Update
Daniel Carlson
-
May 2, 2023
0
Front Page
TFF Pharmaceuticals Receives Additional Funding from Leidos to Advance Next-Generation Personalized...
Daniel Carlson
-
May 1, 2023
0
Front Page
This Time It’s Different!
Daniel Carlson
-
April 29, 2023
10
Front Page
April 27th, 2023 Trade Update…ATOM and INAB
Daniel Carlson
-
April 27, 2023
1
Atomera
Atomera Signs Commercial License Agreement with STMicroelectronics
Daniel Carlson
-
April 26, 2023
1
Front Page
April 26, 2023 Trade Update
Daniel Carlson
-
April 26, 2023
5
Front Page
IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in...
Daniel Carlson
-
April 26, 2023
0
Front Page
Spectra7 Announces 107% Revenue Growth for 2022, Pre-announces Q1 2023 and...
Daniel Carlson
-
April 26, 2023
0
Front Page
IN8bio Presents Positive, New INB-100 Data Showing Long-term Complete Remissions and...
Daniel Carlson
-
April 24, 2023
0
Front Page
Anixa Delivers On The Data While The Stock Rollercoasters
Daniel Carlson
-
April 22, 2023
3
Front Page
XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer’s Disease
Daniel Carlson
-
April 19, 2023
0
Anixa
Recapping Anixa…Premium Subscriber Update
Daniel Carlson
-
April 18, 2023
5
Anixa
Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1...
Daniel Carlson
-
April 17, 2023
0
Anixa
Anixa’s Breast Cancer Vaccine Looks Spot On…An Interview With Dr. Amit...
Daniel Carlson
-
April 17, 2023
1
Front Page
IN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches...
Daniel Carlson
-
April 17, 2023
0
Front Page
Coming Out Of Hibernation?
Daniel Carlson
-
April 15, 2023
7
Front Page
Lantern Pharma Receives Notice of Allowance for Composition of Matter Patent...
Daniel Carlson
-
April 13, 2023
0
Front Page
IN8bio to Present New Positive Clinical Data from Phase 1 Trial...
Daniel Carlson
-
April 11, 2023
0
Front Page
INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR...
Daniel Carlson
-
April 11, 2023
0
Front Page
How Low Can It Go?
Daniel Carlson
-
April 7, 2023
1
Front Page
INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application...
Daniel Carlson
-
April 3, 2023
0
Front Page
Three Months Down
Daniel Carlson
-
April 1, 2023
5
Front Page
Lantern Pharma Announces First Patient Dosed in the Phase 2 Study,...
Daniel Carlson
-
March 28, 2023
0
Anixa
Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the...
Daniel Carlson
-
March 27, 2023
0
Front Page
3 Dot Lounge…
Daniel Carlson
-
March 25, 2023
5
Front Page
Movano Health Provides Business Update and Reports Fourth Quarter 2022 Financial...
Daniel Carlson
-
March 20, 2023
0
Front Page
Upcoming Catalysts (or, Meaningful Events That Probably Won’t Help Your Portfolio)
Daniel Carlson
-
March 18, 2023
2
Front Page
March 17, 2023 Trade Update
Daniel Carlson
-
March 17, 2023
0
Front Page
IN8bio to Present Positive Preclinical Data on Novel Gamma-Delta CAR Platform...
Daniel Carlson
-
March 16, 2023
0
Front Page
Movano Health Awarded Three New Core Patents Validating its Cutting-Edge Approach...
Daniel Carlson
-
March 14, 2023
0
Front Page
Premium Subscriber Update SPVNF, March 14th
Daniel Carlson
-
March 14, 2023
4
Front Page
Spectra7 Announces 112G PAM4 Design-In with Zhaolong for North American and...
Daniel Carlson
-
March 13, 2023
0
Front Page
Black Swan Diving
Daniel Carlson
-
March 11, 2023
12
Front Page
Spectra7 Microsystems Inc. Announces Private Placement of $5.89 Million CAD
Daniel Carlson
-
March 10, 2023
0
Front Page
Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the...
Daniel Carlson
-
March 8, 2023
0
Front Page
What Women Want: Accuracy is Critical to Future Wearable Use
Daniel Carlson
-
March 7, 2023
4
Front Page
INmune Bio: Things Turning For The Better
Daniel Carlson
-
March 4, 2023
7
Front Page
Premium Subscriber Update INMB, TFFP, SPVNF & BWLKF
Daniel Carlson
-
March 3, 2023
6
Front Page
Lantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing...
Daniel Carlson
-
March 2, 2023
0
Front Page
Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the...
Daniel Carlson
-
February 27, 2023
0
Anixa
Anixa Biosciences Announces Notice of Allowance of Additional Key Patent on...
Daniel Carlson
-
February 27, 2023
0
Front Page
Market Tests Support…Here’s What To Do.
Daniel Carlson
-
February 25, 2023
4
Front Page
Trade Alert for Premium Subscribers, Feb. 23 2023
Daniel Carlson
-
February 23, 2023
4
Front Page
IN8bio Presents Preclinical Data Showing Non-Signaling CAR Platform Targets Cancer Cells...
Daniel Carlson
-
February 23, 2023
0
Anixa
Anixa Biosciences Announces Formation of Breast Cancer Clinical Advisory Board
Daniel Carlson
-
February 22, 2023
0
Front Page
Trading Update for Premium Subscribers, Feb. 18, 2023
Daniel Carlson
-
February 18, 2023
4
Front Page
Execution is Key
Daniel Carlson
-
February 18, 2023
15
Front Page
Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform,...
Daniel Carlson
-
February 15, 2023
0
Front Page
Spectra7 Announces New 800Gbps Design Win with ACES for North American...
Daniel Carlson
-
February 14, 2023
0
Front Page
Ruminating On INmune, Anixa and More
Daniel Carlson
-
February 11, 2023
18
Front Page
Spectra7 Targets High Growth 800Gbps AI Server Market
Daniel Carlson
-
February 9, 2023
0
Front Page
TFF Pharmaceuticals Appoints Harlan Weisman, M.D. as Permanent Chief Executive Officer
Daniel Carlson
-
February 8, 2023
0
Front Page
INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development...
Daniel Carlson
-
February 8, 2023
0
Front Page
Trading Update, February 8th 2023
Daniel Carlson
-
February 8, 2023
1
Front Page
Double Trouble
Daniel Carlson
-
February 3, 2023
9
Front Page
Spectra7 to Showcase 200 and 400Gbps Connectivity using Active Copper Cables...
Daniel Carlson
-
February 3, 2023
0
Uncategorized
Awaiting Liftoff…Catalyst List
Daniel Carlson
-
January 27, 2023
6
Front Page
Trading Update, January 27th 2023
Daniel Carlson
-
January 27, 2023
0
Front Page
Movano Health Prices $6.5 Million Public Offering
Daniel Carlson
-
January 27, 2023
0
Front Page
INmune in DMD…Yet Another Indication of Future Success
Daniel Carlson
-
January 25, 2023
0
Front Page
INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach...
Daniel Carlson
-
January 25, 2023
0
Front Page
Looking for 3-5X This Year? These Two Jackpot Stocks Offer That...
Daniel Carlson
-
January 21, 2023
2
Front Page
Spectra7 Announces Preliminary Fourth Quarter and Annual Financial Results for the...
Daniel Carlson
-
January 18, 2023
0
enVVeno
enVVeno Medical Promotes Dr. Hamed Alavi to Senior Vice President and...
Daniel Carlson
-
January 18, 2023
0
Front Page
Notes for Premium Subscribers
Daniel Carlson
-
January 17, 2023
9
Front Page
Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path...
Daniel Carlson
-
January 17, 2023
0
Front Page
The January Halftime Report
Daniel Carlson
-
January 14, 2023
4
Front Page
The 2023 Game Plan
Daniel Carlson
-
January 10, 2023
1
Front Page
Spectra7, ACON, and Mo-Link to Demonstrate Thunderbolt 4 Active Copper Cables...
Daniel Carlson
-
January 10, 2023
0
Front Page
TFF Pharmaceuticals Announces the Appointment of Zamaneh Mikhak, M.D. as Chief...
Daniel Carlson
-
January 9, 2023
6
Front Page
For The TW Portfolio, Our FATE Awaits
Daniel Carlson
-
January 7, 2023
6
Uncategorized
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284...
Daniel Carlson
-
January 5, 2023
0
Front Page
IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals
Daniel Carlson
-
January 5, 2023
2
Front Page
IN8bio to Present at Biotech Showcase 2023 in San Francisco
Daniel Carlson
-
January 3, 2023
0
Front Page
The Light at the End of the Tunnel
Daniel Carlson
-
December 31, 2022
9
Front Page
Trading Thoughts As We Prepare To Swap Out The Calendar
Daniel Carlson
-
December 29, 2022
0
Front Page
Movano Health Unveils Evie: First Medical Grade Smart Ring Designed Uniquely...
Daniel Carlson
-
December 28, 2022
2
Front Page
Trading Alert: Initiating a New Position
Daniel Carlson
-
December 19, 2022
3
Front Page
Holiday Cheers!
Daniel Carlson
-
December 17, 2022
0
Front Page
Movano Health On Track to File First FDA Submission for its...
Daniel Carlson
-
December 15, 2022
0
Front Page
Movano Health Announces Launch of Smart Ring Beta Program with Novant...
Daniel Carlson
-
December 15, 2022
0
Front Page
Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative...
Daniel Carlson
-
December 15, 2022
0
Front Page
Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284...
Daniel Carlson
-
December 15, 2022
0
Front Page
Santa Claus Ain’t Coming To Town
Daniel Carlson
-
December 10, 2022
11
Anixa
Anixa Biosciences Announces Maximum Tolerated Dose Reached in Trial of Preventative...
Daniel Carlson
-
December 8, 2022
0
Front Page
INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell...
Daniel Carlson
-
December 8, 2022
2
Front Page
INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to...
Daniel Carlson
-
December 6, 2022
0
Front Page
TFF Pharmaceuticals Announces Leadership Transition
Daniel Carlson
-
December 5, 2022
5
Front Page
Informed Decisions
Daniel Carlson
-
December 3, 2022
8
Front Page
Spectra7 Announces Third Quarter 2022 Financial Results
Daniel Carlson
-
December 3, 2022
0
Front Page
INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance...
Daniel Carlson
-
November 29, 2022
0
Front Page
Pardon Me
Daniel Carlson
-
November 26, 2022
2
Front Page
Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug...
Daniel Carlson
-
November 22, 2022
0
Front Page
Pot Watching…
Daniel Carlson
-
November 19, 2022
14
Front Page
TFF Pharmaceuticals Prices $10.675 Million Offering of Common Stock and Warrants
Daniel Carlson
-
November 18, 2022
10
Front Page
Trading Blog, November 17, 2022
Daniel Carlson
-
November 17, 2022
5
Front Page
Positive 3-Year VenoValve® First-in-Human Data Presented at 49th Annual VEITH Symposium...
Daniel Carlson
-
November 17, 2022
0
Front Page
Trading Blog, November 16, 2022
Daniel Carlson
-
November 16, 2022
3
Front Page
INmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence...
Daniel Carlson
-
November 14, 2022
0
Front Page
Crashing Bitcoins and Other Thoughts
Daniel Carlson
-
November 12, 2022
18
Anixa
Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the...
Daniel Carlson
-
November 9, 2022
0
Front Page
enVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve...
Daniel Carlson
-
November 7, 2022
0
Front Page
Dinner Table Talk
Daniel Carlson
-
November 5, 2022
12
Front Page
ParkerVision Secures Patent License Agreement with Hisense
Daniel Carlson
-
November 3, 2022
3
Front Page
TFF Pharmaceuticals Announces Collaboration with Aptar Pharma to Explore and Develop...
Daniel Carlson
-
November 3, 2022
6
Front Page
TFF Delays Data and Other Thoughts Heading Into Year-End 2022
Daniel Carlson
-
November 2, 2022
2
Front Page
TFF Pharmaceuticals Announces Program Updates for Voriconazole Inhaled Powder and Tacrolimus...
Daniel Carlson
-
November 1, 2022
12
Front Page
TFF Pharmaceuticals Announces Second Patient Successfully Treated with Voriconazole Inhalation Powder...
Daniel Carlson
-
November 1, 2022
5
Front Page
Sanford M. Litvack Joins ParkerVision Board of Directors
Daniel Carlson
-
November 1, 2022
0
Anixa
Dr. Jose Conejo-Garcia, Invited to Present Keynote Address at Duke Cancer...
Daniel Carlson
-
October 31, 2022
0
Front Page
Counting Down to Catalysts
Daniel Carlson
-
October 29, 2022
13
Front Page
Spectra7 Announces Return of Chief Executive Officer Raouf Halim to Half...
Daniel Carlson
-
October 29, 2022
1
Front Page
enVVeno Medical Reports Third Quarter 2022 Financial Results and Provides Corporate...
Daniel Carlson
-
October 28, 2022
0
Anixa
Anixa Biosciences Announces Commencement of Phase 1b Trial of its Breast...
Daniel Carlson
-
October 26, 2022
0
Front Page
Keeping An Eye On The Trees
Daniel Carlson
-
October 22, 2022
5
Front Page
Lantern Pharma Announces Issuance of New Patent that Strengthens Patent Portfolio...
Daniel Carlson
-
October 20, 2022
0
Front Page
INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple...
Daniel Carlson
-
October 19, 2022
0
Front Page
Resetting Expectations
Daniel Carlson
-
October 15, 2022
7
Front Page
Spectra7 Announces Preliminary Third Quarter 2022 Revenue and Second Half 2022...
Daniel Carlson
-
October 15, 2022
0
Front Page
TFF Pharmaceuticals Announces Presentation of Data Featuring Applications of Thin Film...
Daniel Carlson
-
October 11, 2022
4
Anixa
Anixa Biosciences Announces Presentation on Ovarian Cancer CAR-T Therapy Trial at...
Daniel Carlson
-
October 10, 2022
0
Front Page
Bringing Down the House
Daniel Carlson
-
October 8, 2022
21
Front Page
Welcome Back???
Daniel Carlson
-
October 1, 2022
7
Front Page
enVVeno Medical Announces the Development of a Transcatheter Based Replacement Venous...
Daniel Carlson
-
September 27, 2022
0
Front Page
Trading Alert, Sept. 15th, 2022
Daniel Carlson
-
September 15, 2022
0
Front Page
Lantern Pharma to Present Positive Preclinical Data on the Efficacy of...
Daniel Carlson
-
September 14, 2022
0
Anixa
Anixa Biosciences’ Ovarian Cancer CAR-T Therapy to be Presented at the...
Daniel Carlson
-
September 12, 2022
0
Front Page
Moving Day
Daniel Carlson
-
September 10, 2022
15
Front Page
TFF Pharmaceuticals Announces Presentation of Patient Data with Voriconazole Inhalation Powder...
Daniel Carlson
-
September 8, 2022
1
Front Page
Don’t Fight The FED. TW’s August Recap.
Daniel Carlson
-
September 3, 2022
0
Front Page
The Bear Returns
Daniel Carlson
-
August 27, 2022
9
Uncategorized
Spectra7 Announces Closing of the Upsized Convertible Debenture Financing of $8.9...
Daniel Carlson
-
August 27, 2022
0
Front Page
Spectra7 Announces Upsizing of Convertible Debenture Financing to $9.0 Million
Daniel Carlson
-
August 23, 2022
0
Front Page
When News Is Good
Daniel Carlson
-
August 20, 2022
0
Front Page
Trading Alert, August 18th, 2022
Daniel Carlson
-
August 18, 2022
0
Front Page
enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations
Daniel Carlson
-
August 16, 2022
0
Anixa
CAR-T Trial Launches…An Interview With Dr. Amit Kumar, CEO of Anixa
Daniel Carlson
-
August 15, 2022
1
Anixa
Anixa Biosciences Announces Treatment of First Patient in its Ovarian Cancer...
Daniel Carlson
-
August 15, 2022
0
Front Page
Pendulum Swings
Daniel Carlson
-
August 13, 2022
5
Front Page
Movano Expands Go-To-Market Team with Vice President of UX and UI...
Daniel Carlson
-
August 12, 2022
0
Front Page
Movano Ring Exceeds Accuracy Targets for SpO2 and Heart Rate Monitoring...
Daniel Carlson
-
August 9, 2022
0
Front Page
The Domino Effect
Daniel Carlson
-
August 6, 2022
11
Front Page
Trading Alert, August 5th, 2022
Daniel Carlson
-
August 5, 2022
0
Front Page
Trading Alert, August 2nd, 2022
Daniel Carlson
-
August 2, 2022
0
Front Page
Micros Rallied in July, Can It Continue?
Daniel Carlson
-
July 30, 2022
3
Front Page
Spectra7 Announces $8.0 Million Convertible Debenture Financing; Closing of First Tranche
Daniel Carlson
-
July 27, 2022
0
Fortress Bio
Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral...
Daniel Carlson
-
July 27, 2022
0
Uncategorized
INmune Bio, Inc. CEO, Raymond J. Tesi, MD, to Participate in...
Daniel Carlson
-
July 25, 2022
0
Front Page
Dog Days of Summer
Daniel Carlson
-
July 23, 2022
1
Anixa
Anixa Biosciences Announces Notice of Allowance of Additional Patent on Breast...
Daniel Carlson
-
July 21, 2022
2
Front Page
Trading Alert, July 19th, 2022
Daniel Carlson
-
July 19, 2022
2
Front Page
Taking the Long View on TFF
Daniel Carlson
-
July 16, 2022
0
Front Page
TFF Pharmaceuticals Expands R&D Operations with New Austin Facility
Daniel Carlson
-
July 14, 2022
3
Front Page
Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical...
Daniel Carlson
-
July 14, 2022
0
Front Page
Catalysts Aplenty, a 2nd Half Preview
Daniel Carlson
-
July 9, 2022
1
Front Page
Texas Court Grants ParkerVision Motion to Add Willfulness to Intel Complaint
Daniel Carlson
-
July 8, 2022
2
Front Page
enVVeno Medical Announces the Issuance of a New Unique Category III...
Daniel Carlson
-
July 8, 2022
0
Amryt
Amryt Presents New Analyses from the EASE Phase 3 Trial in...
Daniel Carlson
-
July 7, 2022
0
Front Page
June in Review
Daniel Carlson
-
July 1, 2022
3
Front Page
This Week’s Newsletter
Daniel Carlson
-
June 25, 2022
0
Amryt
European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional...
Daniel Carlson
-
June 23, 2022
0
Front Page
Spectra7 Expands Availability of Active Copper Cables with new Design-in with...
Daniel Carlson
-
June 23, 2022
0
Front Page
USPTO Issues Patent Covering Use of XPro™ for Treatment of CNS...
Daniel Carlson
-
June 22, 2022
2
Anixa
Anixa Biosciences Announces Publication of Peer-Reviewed Journal Article in Clinical and...
Daniel Carlson
-
June 21, 2022
0
Anixa
Going Downhill
Daniel Carlson
-
June 18, 2022
2
Front Page
INmune Bio, Inc. Presents Data on Combination Therapy with INB03™ on...
Daniel Carlson
-
June 16, 2022
0
Amryt
Amryt Presents Data for Mycapssa® (oral octreotide) from OPTIMAL and MPOWERED...
Daniel Carlson
-
June 13, 2022
0
Anixa
High Degree of Confidence
Daniel Carlson
-
June 9, 2022
7
Amryt
Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials...
Daniel Carlson
-
June 8, 2022
0
Atomera
June Gloom
Daniel Carlson
-
June 4, 2022
0
Fortress Bio
Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial...
Daniel Carlson
-
May 31, 2022
0
Front Page
Spectra7 Announces First Quarter 2022 Financial Results
Daniel Carlson
-
May 31, 2022
0
Front Page
Establishing Lows
Daniel Carlson
-
May 28, 2022
2
Front Page
INMB: Making Sense of The FDA Clinical Hold
Daniel Carlson
-
May 25, 2022
5
Front Page
INmune Bio, Inc. to Provide Additional Manufacturing Information to FDA as...
Daniel Carlson
-
May 23, 2022
1
Anixa
CEO Knows Best
Daniel Carlson
-
May 21, 2022
2
Fortress Bio
Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency...
Daniel Carlson
-
May 19, 2022
0
Front Page
Quest Resource Holding Corporation Reports First Quarter 2022 Financial Results
Daniel Carlson
-
May 16, 2022
0
Front Page
INmune Bio Looks to Change The CNS Landscape
Daniel Carlson
-
May 16, 2022
1
Front Page
It’s Still The Early Innings
Daniel Carlson
-
May 14, 2022
11
Front Page
Movano Successfully Completes Functional Testing of Smallest Ever Custom mmWave Sensor...
Daniel Carlson
-
May 13, 2022
2
Front Page
TFF Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business...
Daniel Carlson
-
May 11, 2022
4
Front Page
INmune Bio, Inc. Presents Data Demonstrating XPro™ Promotes Remyelination in Gray...
Daniel Carlson
-
May 10, 2022
1
Anixa
Stepping on Rakes
Daniel Carlson
-
May 7, 2022
0
Front Page
INmune Bio, Inc. Announces First Quarter 2022 Results and Provides Business...
Daniel Carlson
-
May 5, 2022
0
Front Page
Top Global Virtual Reality Gaming Company Chooses Spectra7 Chipset to Power...
Daniel Carlson
-
May 5, 2022
0
Front Page
enVVeno Medical Reports First Quarter 2022 Financial Results and Provides Corporate...
Daniel Carlson
-
May 2, 2022
0
Front Page
TFF Pharmaceuticals Announces Multiple Presentations Highlighting Broad Applicability of its Thin...
Daniel Carlson
-
May 2, 2022
0
Front Page
Spectra7 Announces Fourth Quarter and Fiscal Year 2021 Financial Results
Daniel Carlson
-
May 2, 2022
0
Anixa
The Rolling Correction Gathers Steam…
Daniel Carlson
-
April 30, 2022
3
Anixa
Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the...
Daniel Carlson
-
April 28, 2022
2
Atomera
Atomera Provides First Quarter 2022 Results
Daniel Carlson
-
April 27, 2022
0
Atomera
Atomera Enters into Joint Development Agreement with Major Foundry
Daniel Carlson
-
April 27, 2022
0
Front Page
Does Nkarta’s Positive NK Data Have Any Relation To INmune Bio’s...
Daniel Carlson
-
April 25, 2022
0
Fortress Bio
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106, CD20-Targeted...
Daniel Carlson
-
April 25, 2022
2
Amryt
It’s A Process
Daniel Carlson
-
April 23, 2022
7
Amryt
CHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic...
Daniel Carlson
-
April 22, 2022
0
Front Page
TFF Announces Data from Phase 1 Study of Niclosamide
Daniel Carlson
-
April 19, 2022
3
Front Page
Movano Hires Chief Marketing Officer to Implement Its Multi-Channel Marketing Strategy...
Daniel Carlson
-
April 18, 2022
0
Company
How’s Your Balance (Sheet)?
Daniel Carlson
-
April 16, 2022
8
Atomera
Atomera Successfully Meets Requirements of Joint Development Agreement
Daniel Carlson
-
April 14, 2022
1
Front Page
INmune Bio Announces First Patient Dosed in Phase 2 XPro1595 Trial...
Daniel Carlson
-
April 13, 2022
0
Amryt
Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa® (oral...
Daniel Carlson
-
April 13, 2022
0
Front Page
INmune Bio, Inc. to Present Preclinical Data on INB03 at the...
Daniel Carlson
-
April 12, 2022
0
Front Page
Your Home Is Worth What???
Daniel Carlson
-
April 9, 2022
5
Anixa
Anixa Zoom Recap
Daniel Carlson
-
April 7, 2022
1
Front Page
Spectra7 Announces Preliminary First Quarter 2022 Revenue and Provides Business Update
Daniel Carlson
-
April 7, 2022
0
Anixa
Anixa Biosciences’ Ovarian Cancer CAR-T Therapy to be Discussed at The...
Daniel Carlson
-
April 6, 2022
0
Front Page
All Coming Together
Daniel Carlson
-
April 5, 2022
0
Front Page
INmune Bio, Inc. Highlights INKmune™ Data Featured in NK Cells in...
Daniel Carlson
-
April 4, 2022
0
Front Page
The New Reality
Daniel Carlson
-
April 2, 2022
2
Anixa
Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase...
Daniel Carlson
-
March 30, 2022
6
Front Page
Spectra7 Partners with Volex to Deliver Next Generation 800Gbps Data Center...
Daniel Carlson
-
March 30, 2022
0
Front Page
INmune Bio, Inc. Announces Company’s CSO Dr. Mark Lowdell to Co-Host...
Daniel Carlson
-
March 30, 2022
0
Front Page
enVVeno Medical Reports Fourth Quarter and Year-End 2021 Financial Results and...
Daniel Carlson
-
March 28, 2022
0
Front Page
Separating the Wheat From the Chaff
Daniel Carlson
-
March 26, 2022
8
Front Page
INmune Bio, Inc. Spotlights Key Findings in Presentations at AD/PD™ 2022
Daniel Carlson
-
March 25, 2022
0
Front Page
Movano Inc. Provides Business Update and Reports Fourth Quarter 2021 Financial...
Daniel Carlson
-
March 25, 2022
0
Front Page
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results...
Daniel Carlson
-
March 24, 2022
2
Front Page
Update on INmune, TFF Pharma and DarioHealth
Daniel Carlson
-
March 24, 2022
5
Fortress Bio
Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce CUTX-101, Copper Histidinate,...
Daniel Carlson
-
March 21, 2022
0
Front Page
Buy The Rumor, Sell The News
Daniel Carlson
-
March 19, 2022
3
Front Page
For Those Looking To Play A Bounce, Here’s A Candidate
Daniel Carlson
-
March 18, 2022
0
Front Page
TFF Pharmaceuticals Enters into CRADA with the U.S. Army and The...
Daniel Carlson
-
March 17, 2022
3
Front Page
INmune Bio, Inc. Announces Nine Data Presentations at AD/PD™ 2022 –...
Daniel Carlson
-
March 15, 2022
0
Anixa
Groundhog Day
Daniel Carlson
-
March 12, 2022
12
Front Page
Orlando Court Grants Qualcomm Motion Blocking ParkerVision’s Presentation of Key Evidence...
Daniel Carlson
-
March 11, 2022
2
Front Page
QUEST RESOURCE HOLDING CORPORATION ANNOUNCES STRONG PRELIMINARY FOURTH QUARTER 2021 FINANCIAL...
Daniel Carlson
-
March 10, 2022
0
Anixa
ANIX Update
Daniel Carlson
-
March 9, 2022
1
Front Page
One-Year VenoValve(R) Data Published in Peer-Reviewed Journal, Vascular and Endovascular Surgery
Daniel Carlson
-
March 9, 2022
0
Amryt
Amryt Announces 22% growth in FY 2021 Revenues to $222.5M
Daniel Carlson
-
March 9, 2022
0
Amryt
Amryt Announces Successful Bioavailability Study for Mycapssa® (octreotide capsules)
Daniel Carlson
-
March 8, 2022
0
Front Page
This Trend is NOT Your Friend
Daniel Carlson
-
March 5, 2022
8
Front Page
INmune, a very brief update
Daniel Carlson
-
March 4, 2022
3
Atomera
Atomera’s Enhanced MSTcad Helps Chip Companies Quickly Realize MST Benefits
Daniel Carlson
-
March 3, 2022
0
Front Page
TFF Pharmaceuticals and Catalent Announce New Inhalation Dry Powder Development and...
Daniel Carlson
-
March 1, 2022
3
Front Page
TFFP: More Thoughts Regarding NICLOSAMIDE
Daniel Carlson
-
February 28, 2022
3
Amryt
Amryt Receives Complete Response Letter from the FDA for Oleogel-S10 NDA
Daniel Carlson
-
February 28, 2022
0
Amryt
Putin It In Perspective
Daniel Carlson
-
February 25, 2022
7
Front Page
Positive Long-Term VenoValve® First-in-Human Data Presented at 34th Annual Meeting of...
Daniel Carlson
-
February 25, 2022
5
Front Page
TFF Pharmaceuticals Announces Inhaled Niclosamide Significantly Inhibits Viral Replication of the...
Daniel Carlson
-
February 24, 2022
5
Front Page
Good News
Daniel Carlson
-
February 19, 2022
1
Front Page
enVVeno Medical Announces ISO 13485 Certification
Daniel Carlson
-
February 19, 2022
0
Front Page
Updating My Thinking On INmune (INMB) and TFF Pharma (TFFP)
Daniel Carlson
-
February 18, 2022
6
Front Page
Movano Completes its Second Glucose Pilot Study
Daniel Carlson
-
February 18, 2022
0
Front Page
Movano Announces Two Key Hires to Further Its Go-To-Market Strategy for...
Daniel Carlson
-
February 15, 2022
0
Atomera
End Game
Daniel Carlson
-
February 12, 2022
2
Atomera
Quest and Atomera Spike…Should You Be A Buyer?
Daniel Carlson
-
February 10, 2022
0
Atomera
Atomera Licenses MST® Technology to Semiconductor Foundry
Daniel Carlson
-
February 8, 2022
0
Front Page
Updates From Several Management Calls
Daniel Carlson
-
February 6, 2022
4
Atomera
Metamorphosis
Daniel Carlson
-
February 5, 2022
2
Front Page
This Week’s Billboard Headline…Glenn Mattes Stars As Rocky Balboa!
Daniel Carlson
-
January 29, 2022
6
Amryt
Amryt Announces Oleogel-S10 EMA Regulatory Update
Daniel Carlson
-
January 28, 2022
0
Front Page
Spectra7: Hyper-Growth in Hyper-Scale Data Centers
Daniel Carlson
-
January 27, 2022
0
Front Page
TFF Pharmaceuticals Completes Enrollment in Phase 1 Study Evaluating Inhaled Formulation...
Daniel Carlson
-
January 27, 2022
0
Front Page
INmune Bio, Inc. Announces Research Collaboration with Chinese University of Hong...
Daniel Carlson
-
January 25, 2022
0
Fortress Bio
Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of...
Daniel Carlson
-
January 25, 2022
0
Front Page
PTAB Issues Rulings in ParkerVision IPRs Filed by Intel
Daniel Carlson
-
January 25, 2022
0
Front Page
Spectra7 Announces Preliminary Fourth Quarter 2021 Revenue and Record Order Backlog...
Daniel Carlson
-
January 24, 2022
0
Front Page
Lantern Pharma Receives Rare Pediatric Disease and Orpan Drug Designations for...
Daniel Carlson
-
January 24, 2022
0
Anixa
Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease...
Daniel Carlson
-
January 24, 2022
0
Front Page
Welcome To The Terrordome
Daniel Carlson
-
January 22, 2022
3
Front Page
An INKmune Update, Catalysts Included…
Daniel Carlson
-
January 17, 2022
0
Anixa
ParkerVision’s Time is Nigh…
Daniel Carlson
-
January 15, 2022
4
Front Page
Lantern Pharma Expands Precision Oncology Collaboration with the National Cancer Institute...
Daniel Carlson
-
January 13, 2022
0
Fortress Bio
Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule...
Daniel Carlson
-
January 13, 2022
0
Amryt
Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role...
Daniel Carlson
-
January 11, 2022
0
Anixa
Welcome to 2022?
Daniel Carlson
-
January 8, 2022
6
Front Page
Movano Completes Blood Pressure Study with 110 Participants
Daniel Carlson
-
January 3, 2022
0
Amryt
Happy New Year!!!
Daniel Carlson
-
January 1, 2022
8
Front Page
Movano Unveils Smart Ring Designed for Women Seeking More Approachable Health...
Daniel Carlson
-
December 27, 2021
3
Front Page
Trading Blog, December 22, 2021
Daniel Carlson
-
December 22, 2021
0
Front Page
TFF Pharmaceuticals Announces Final Data from Phase 1b Study of Inhaled...
Daniel Carlson
-
December 21, 2021
1
Front Page
Who Believes? Santa Rally Coming…
Daniel Carlson
-
December 18, 2021
14
Front Page
Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in...
Daniel Carlson
-
December 14, 2021
0
Front Page
No QUESTion, This Stock’s A Winner
Daniel Carlson
-
December 11, 2021
4
Front Page
INmune Bio, Inc. Announces Key Breast Cancer Treatment Resistance Data to...
Daniel Carlson
-
December 9, 2021
0
Front Page
Quest Resource Holding Acquires Two Asset-Light Waste Services Companies
Daniel Carlson
-
December 8, 2021
0
Anixa
Anixa Biosciences and MolGenie Announce that their COVID-19 Compounds are Expected...
Daniel Carlson
-
December 7, 2021
0
Fortress Bio
Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce the Initiation of...
Daniel Carlson
-
December 7, 2021
0
Front Page
TFF Pharmaceuticals Hosting Science Day on December 13, 2021
Daniel Carlson
-
December 6, 2021
0
Anixa
Bottom Picking
Daniel Carlson
-
December 4, 2021
3
Front Page
INmune Bio, Inc. Announces Two Presentations at the 2021 British Society...
Daniel Carlson
-
December 1, 2021
0
Atomera
Atomera Breathes New Life into Moore’s Law for Power and Analog...
Daniel Carlson
-
November 30, 2021
0
Front Page
Is OMICRON Potentially Positive For TFF Pharma?
Daniel Carlson
-
November 29, 2021
8
Fortress Bio
Avenue Therapeutics Announces FDA Advisory Committee Meeting to Review IV Tramadol...
Daniel Carlson
-
November 29, 2021
0
Anixa
Turkey Shoot…December Preview
Daniel Carlson
-
November 26, 2021
2
Front Page
Trading Blog, November 23rd, 2021
Daniel Carlson
-
November 23, 2021
0
Amryt
Amryt Provides Update on Regulatory Review Process for Oleogel-S10
Daniel Carlson
-
November 23, 2021
0
Amryt
Amryt Pharma plc Announces the Cancellation of Admission of its Ordinary...
Daniel Carlson
-
November 22, 2021
0
Front Page
Lantern Pharma Announces Share Repurchase Program
Daniel Carlson
-
November 22, 2021
0
Front Page
The Worst Bull Market Ever
Daniel Carlson
-
November 20, 2021
6
Front Page
Trading Blog, November 18th, 2021
Daniel Carlson
-
November 18, 2021
0
Atomera
Atomera Reaches 300 Patents Focused on Perfecting Atomic Level Engineering and...
Daniel Carlson
-
November 17, 2021
0
Front Page
Quest Resource Holding Corp. Reports 3rd Quarter 2021 Financial Results
Daniel Carlson
-
November 16, 2021
0
Fortress Bio
Fortress Biotech Reports Record Third Quarter 2021 Financial Results and Recent...
Daniel Carlson
-
November 16, 2021
0
Front Page
TFF Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business...
Daniel Carlson
-
November 16, 2021
0
Front Page
Three Non-Biotech Stocks
Daniel Carlson
-
November 12, 2021
4
Fortress Bio
Journey Medical Corporation Prices $35.2 Million Initial Public Offering
Daniel Carlson
-
November 12, 2021
0
Front Page
Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Glioblastoma Accepted...
Daniel Carlson
-
November 11, 2021
0
Front Page
enVVeno Medical Reports Third Quarter 2021 Financial Results and Provides Corporate...
Daniel Carlson
-
November 11, 2021
5
Front Page
QUEST RESOURCE HOLDING CORPORATION ACQUIRES ASSET-LIGHT WASTE SERVICES PROVIDER
Daniel Carlson
-
November 11, 2021
0
Front Page
Notes from INKmune Update
Daniel Carlson
-
November 10, 2021
3
Front Page
Trading Blog, November 9th, 2021
Daniel Carlson
-
November 9, 2021
6
Front Page
LexaGene Expands Bio-Pharma Contamination Panel by Adding Test that includes a...
Daniel Carlson
-
November 9, 2021
0
Front Page
TFF Pharmaceuticals Announces Completion of Dosing of Phase 1b Study for...
Daniel Carlson
-
November 8, 2021
1
Anixa
Asymmetric Risk
Daniel Carlson
-
November 6, 2021
5
Front Page
Lantern Pharma Announces Abstract on Effectiveness of LP-284 in Hematologic Cancers...
Daniel Carlson
-
November 4, 2021
0
Front Page
INmune Bio, Inc. Announces Third Quarter 2021 Results and Provides Business...
Daniel Carlson
-
November 3, 2021
4
Amryt
Amryt Reports Strong Q3 2021 Results
Daniel Carlson
-
November 3, 2021
0
Front Page
ParkerVision Receives Favorable Markman Recommendations in ParkerVision v. Hisense and TCL
Daniel Carlson
-
November 2, 2021
0
Front Page
Lantern Pharma Reports Third Quarter 2021 Financial Results and Operating Highlights
Daniel Carlson
-
November 1, 2021
0
Front Page
Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®,...
Daniel Carlson
-
November 1, 2021
0
Atomera
Trick or Treat? October Review
Daniel Carlson
-
October 30, 2021
4
Front Page
LexaGene Completes First Stage of U.S. ARMY DEVCOM Agreement
Daniel Carlson
-
October 29, 2021
0
Atomera
Atomera Provides Third Quarter 2021 Results
Daniel Carlson
-
October 28, 2021
0
Front Page
TFF Pharmaceuticals Receives Approval from Health Canada to Enter Human Clinical...
Daniel Carlson
-
October 28, 2021
0
Front Page
Code Ocean Selected by Lantern Pharma to Power A.I. and Computational...
Daniel Carlson
-
October 27, 2021
0
Front Page
INmune Bio, Inc. Announces Multiple Oral and Poster Presentations at the...
Daniel Carlson
-
October 27, 2021
0
Front Page
Trading Blog, October 26th, 2021
Daniel Carlson
-
October 26, 2021
0
Anixa
Anixa Biosciences Announces Patient Dosing of its Investigational Vaccine Candidate in...
Daniel Carlson
-
October 26, 2021
0
Front Page
LexaGene Completes Analytical Studies for FDA EUA of COVID-19 Testing
Daniel Carlson
-
October 25, 2021
0
Anixa
Training My Thoughts
Daniel Carlson
-
October 22, 2021
0
Front Page
enVVeno Medical Reports Successful Completion of First VenoValve Surgery for U.S....
Daniel Carlson
-
October 22, 2021
0
Amryt
Amryt Announces New Patents for Oleogel-S10 and Mycapssa®
Daniel Carlson
-
October 19, 2021
0
Anixa
Saturday Morning Musings
Daniel Carlson
-
October 16, 2021
6
Front Page
Why TFF’s Hamster Data Is Bigger Than Investors Think
Daniel Carlson
-
October 15, 2021
2
Front Page
Trading Blog, October 14th, 2021
Daniel Carlson
-
October 14, 2021
0
Front Page
TFF Pharmaceuticals and Augmenta Bioworks Publish Positive In Vivo Data Showing...
Daniel Carlson
-
October 14, 2021
0
Front Page
Ondas Holdings Inc. Announces Strategic Partnership with Dynam.AI
Daniel Carlson
-
October 11, 2021
0
Anixa
$8 Paddle Balls?
Daniel Carlson
-
October 9, 2021
2
Fortress Bio
Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101,...
Daniel Carlson
-
October 8, 2021
0
Front Page
LexaGene’s Largest Study Validates Accuracy of its Veterinary Test Panel
Daniel Carlson
-
October 7, 2021
0
Anixa
Anixa Biosciences Announces First Chinese Patent on its CAR-T Cancer Therapy...
Daniel Carlson
-
October 6, 2021
2
Front Page
Trading Blog, October 5th, 2021
Daniel Carlson
-
October 5, 2021
3
Amryt
October Awaits
Daniel Carlson
-
October 2, 2021
2
Anixa
Anixa Biosciences Announces Notice of Allowance for Additional Patent on its...
Daniel Carlson
-
October 1, 2021
0
Front Page
LexaGene Reports on Recent Veterinary Trade Shows
Daniel Carlson
-
September 30, 2021
0
Fortress Bio
Fortress Biotech Announces Receipt of Notice of Option Exercise from AstraZeneca...
Daniel Carlson
-
September 29, 2021
0
Front Page
Trading Blog, Sept. 28th, 2021
Daniel Carlson
-
September 28, 2021
0